Sylvain Ladoire
Dijon, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 161 publications
Prognostic Value of a Composite Score Incorporating Baseline [18F]FDG PET/CT and [68Ga]Ga-PSMA-11 PET/CT When Screening for [177Lu]Lu-PSMA Treatment Eligibility (PROFILE Study).
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: February 23, 2026
Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancer.
Journal: ESMO open
Published: November 04, 2025
An expression signature of 19 human endogenous retroviruses identifies immunogenic luminal breast cancers likely to respond to immunotherapy.
Journal: Frontiers in oncology
Published: October 19, 2025
Chemo-prAIdict Breast: A deep learning solution for predicting residual disease on biopsies of breast cancer patients treated with neoadjuvant chemotherapy.
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 11, 2025
PROMENADE: pembrolizumab for early ER-low/HER2-negative breast cancer, real-world French cohort.
Journal: ESMO open
Published: July 08, 2025
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer.
Journal: The New England journal of medicine
Published: June 02, 2025
Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 Study.
Journal: European urology
Published: March 24, 2025
How can we optimize the surgical management of the axilla in breast cancer since the MonarchE trial?
How can we optimize the surgical management of the axilla in breast cancer since the MonarchE trial?
Journal: Breast cancer research and treatment
Published: November 15, 2024
Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib.
Journal: NPJ breast cancer
Published: November 01, 2024
Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 23, 2024
Value of early metabolic response for predicting axillary pathological complete response during neoadjuvant systemic therapy in triple negative and HER2-amplified breast cancers: impact of tumor subtypes.
Journal: Cancer imaging : the official publication of the International Cancer Imaging Society
Published: October 07, 2024
Exploring the role of ESR1 mutations in metastatic hormone receptor-positive breast cancer T cell immune surveillance disruption.
Journal: Breast cancer research : BCR
Published: August 26, 2024
Last Updated: 09/26/2026